The E743–77-pulsed bm12 mBMDC vaccine is superior to WT and bm1 mBMDC vaccines in delaying TC-1 tumor growth and improves antigen-specific CD8+ T cell responses and proinflammatory Th1 and Th17 responses. The gene discussed is CD8A; the disease is neoplasm.